What to Expect from Guardian Pharmacy Service's Earnings
Benzinga Insights 8 months ago
Earnings
Guardian Pharmacy Service (NYSE:GRDN) is gearing up to announce its quarterly earnings on Wednesday, 2026-03-11. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Guardian Pharmacy Service will report an earnings per share (EPS) of $0.26.
Guardian Pharmacy Service bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Earnings History Snapshot
In the previous earnings release, the company beat EPS by $0.03, leading to a 5.04% increase in the share price the following trading session.
Here's a look at Guardian Pharmacy Service's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.22 | 0.20 | 0.22 | 0.22 |
| EPS Actual | 0.25 | 0.23 | 0.15 | 0.19 |
| Price Change % | 5.04 | 13.78 | -3.98 | 4.35 |
Tracking Guardian Pharmacy Service's Stock Performance
Shares of Guardian Pharmacy Service were trading at $32.34 as of March 09. Over the last 52-week period, shares are up 67.43%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Get to Know Guardian Pharmacy Service Better
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.
Financial Milestones: Guardian Pharmacy Service's Journey
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Guardian Pharmacy Service showcased positive performance, achieving a revenue growth rate of 20.05% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Guardian Pharmacy Service's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 2.6%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Guardian Pharmacy Service's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.56% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Guardian Pharmacy Service's ROA stands out, surpassing industry averages. With an impressive ROA of 2.63%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Guardian Pharmacy Service's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.19.
This article was generated by Benzinga's automated content engine and reviewed by an editor.